Shares of AbCellera ABCL.O rose about 36% to more than a three-year high of $9.41.
The stock was set for its best day on record, if gains held.
The company said a mid-stage trial showed its experimental drug significantly reduces the frequency and severity of moderate-to-severe hot flashes at four weeks versus placebo after a single dose.
ABCL635 is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms, commonly known as hot flashes, due to menopause.
Including session's moves, the stock was up 165% year to date.
ABCL•
